$377 Million is the total value of Cormorant Asset Management, LP's 54 reported holdings in Q2 2014. The portfolio turnover from Q1 2014 to Q2 2014 was 200.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RCPT | Buy | RECEPTOS INC | $20,397,000 | +8.1% | 478,800 | +6.4% | 5.40% | +24.5% |
| OMER | Buy | OMEROS CORP | $19,540,000 | +223.8% | 1,123,000 | +124.6% | 5.18% | +273.1% |
| QCOR | New | QUESTCOR PHARMACEUTICALS INC | $18,498,000 | – | 200,000 | +100.0% | 4.90% | – |
| KPTI | Buy | KARYOPHARM THERAPEUTICS INC | $17,922,000 | +107.2% | 385,000 | +37.5% | 4.75% | +138.8% |
| CELG | New | CELGENE CORP | $17,176,000 | – | 200,000 | +100.0% | 4.55% | – |
| AKBA | New | AKEBIA THERAPEUTICS INC | $11,116,000 | – | 400,000 | +100.0% | 2.95% | – |
| GALT | Buy | GALECTIN THERAPEUTICS INC | $11,048,000 | +107.4% | 800,000 | +129.9% | 2.93% | +139.0% |
| HRTX | New | HERON THERAPEUTICS INC | $8,624,000 | – | 700,000 | +100.0% | 2.28% | – |
| MNKKQ | New | MALLINCKRODT PUB LTD CO | $7,202,000 | – | 90,000 | +100.0% | 1.91% | – |
| NVAX | Buy | NOVAVAX INC | $6,930,000 | +53.0% | 1,500,000 | +50.0% | 1.84% | +76.2% |
| XLRN | New | ACCELERON PHARMA INC | $6,794,000 | – | 200,000 | +100.0% | 1.80% | – |
| SRNE | Buy | SORRENTO THERAPEUTICS INC | $6,750,000 | -24.8% | 1,000,000 | +42.9% | 1.79% | -13.3% |
| VSAR | New | VERSARTIS INC | $5,608,000 | – | 200,000 | +100.0% | 1.49% | – |
| RARE | Buy | ULTRAGENYX PHARMACEUTICAL INC | $5,387,000 | +83.7% | 120,000 | +100.0% | 1.43% | +111.7% |
| AGTC | New | APPLIED GENETIC TECHNOLOGIES | $5,050,000 | – | 218,600 | +100.0% | 1.34% | – |
| New | PUMA BIOTECHNOLOGY INC | $4,500,000 | – | 5,000 | +100.0% | 1.19% | – | |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $4,451,000 | – | 300,000 | +100.0% | 1.18% | – |
| CBPO | New | CHINA BIOLOGIC PRODS INC | $4,447,000 | – | 100,000 | +100.0% | 1.18% | – |
| QTNT | New | QUOTIENT LTD | $4,180,000 | – | 500,000 | +100.0% | 1.11% | – |
| GLYC | Buy | GLYCOMIMETICS INC | $3,981,000 | -48.1% | 472,300 | +0.6% | 1.06% | -40.2% |
| ALDR | New | ALDER BIOPHARMACEUTICALS INC | $3,011,000 | – | 150,000 | +100.0% | 0.80% | – |
| AQXP | Buy | AQUINOX PHARMACEUTICALS INC | $2,829,000 | -10.0% | 300,000 | +21.5% | 0.75% | +3.7% |
| CERU | New | CERULEAN PHARMA INC | $2,610,000 | – | 450,000 | +100.0% | 0.69% | – |
| KIN | New | KINDRED BIOSCIENCES INC | $1,864,000 | – | 100,000 | +100.0% | 0.49% | – |
| AGRX | New | AGILE THERAPEUTICS INC | $1,308,000 | – | 150,000 | +100.0% | 0.35% | – |
| CRIS | New | CURIS INC | $1,116,000 | – | 600,000 | +100.0% | 0.30% | – |
| SCYX | New | SCYNEXIS INC | $802,000 | – | 100,000 | +100.0% | 0.21% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| APELLIS PHARMACEUTICALS INC | 26 | Q1 2024 | 8.6% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| ROCKET PHARMACEUTICALS, INC | 25 | Q1 2024 | 2.4% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rapport Therapeutics, Inc. | June 20, 2024 | 1,283,673 | - |
| CytomX Therapeutics, Inc. | May 13, 2024 | 5,750,000 | - |
| TScan Therapeutics, Inc. | April 29, 2024 | 2,500,000 | - |
| Immuneering Corp | April 15, 2024 | 561,128 | - |
| Ventyx Biosciences, Inc. | March 21, 2024 | 3,670,000 | - |
| Corbus Pharmaceuticals Holdings, Inc. | March 18, 2024 | 2,025,000 | - |
| 89bio, Inc.Sold out | February 14, 2024 | 0 | - |
| Aerovate Therapeutics, Inc.Sold out | February 14, 2024 | 0 | - |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2024 | 2,550,000 | - |
| Ambrx Biopharma, Inc. | February 14, 2024 | 8,725,040 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-09-25 |
| 4 | 2024-09-24 |
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| SC 13G | 2024-06-20 |
| 4 | 2024-06-13 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.